Supernus Pharmaceuticals wins generic knock off case

2016-02-09 07:20:36

(MENAFN- ProactiveInvestors - N.America) Supernus Pharmaceuticals (NASDAQ:SUPN) has won a favorable verdict in its patent dispute with Actavis a maker of generic versions of branded drugs.

Supernus a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases announced that the United States District Court for the District of New Jersey ruled that Actavis infringed US Patent Nos. 7722898 and 7910131 by submitting to the Food and Drug Administration (FDA) a new abbreviated new drug application (ANDA) and seeking permission to market a generic version of Oxtellar XR before the expiration of Supernus's patents.

The court also ruled that US Patent Nos. 7722898 7910131 and 8617600 are valid Supernus added.

Jack Khattar expressed pleasure at the court's verdicts and pledged to vigorously defend the company's intellectual property.

In addition to the above three patents that were subject to the Federal Court decision Oxtellar XR a tablet taken to stave off epileptic fits is further protected by two other patents that are also listed in the FDA's Orange Book which have an expiration date that is no earlier than 2027.

Shares rose almost 20% to $12.125 on Friday and were up 4.3% to $12.65 in pre-market trading on Monday.

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.